Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine ...
2 Views
administrator
07/08/23
Prof Sandip Patel gives a press conference at AACR 2019 on results from the DART phase II trial which showed the combination of ipilimumab and nivolumab to have clinical benefit when treating high-grade neuroendocrine carcinoma.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
-
Category
Show more
Facebook Comments
No comments found